Regcell Co., Ltd., founded in January 2016, is a university-originated biotechnology company based on the pioneering research of Dr. Shimon Sakaguchi, Nobel Laureate in Physiology or Medicine and discoverer of regulatory T (Treg) cells. The company aims to develop novel therapeutic technologies for autoimmune diseases, graft-versus-host disease, allergy, and cancer through augmenting or suppressing immune responses by targeting Treg cells.
Tregs actively maintain immune homeostasis by suppressing abnormal or excessive immune responses to self and foreign antigens.
Two projects are currently in progress. One is a Treg cell therapy by converting disease-mediating T cells into functionally stable Treg cells in vitro to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.
Tregs actively maintain immune homeostasis by suppressing abnormal or excessive immune responses to self and foreign antigens.
Two projects are currently in progress. One is a Treg cell therapy by converting disease-mediating T cells into functionally stable Treg cells in vitro to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.
Total raised: $45.8M
Investors 2
| Date | Name | Website |
| 10.07.2026 | The Univer... | ut-ec.co.j... |
| 17.04.2025 | Fast Track... | us.fasttra... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.03.2025 | - | $45.8M | - |
Mentions in press and media 2
| Date | Title | Description |
| 15.12.2025 | Нобелевская премия-2025: кто главные бенефициары научных открытий ученых-лауреатов? | Нобелевскую премию вручают за самые передовые открытия — и, конечно, у них есть большой коммерческий потенциал. Право авторства и право на саму разработку — это несколько разные вещи, и возможность получить действительно высокую прибыль буд... |
| 18.03.2025 | RegCell Raises $45.8M in Funding | . RegCell, an Emeryville, CA-based biotechnology company developing therapies for autoimmune diseases and transplantation, raised $45.8M in funding. The round consisted of $8.5M in Seed funding led by The University of Tokyo Edge Capital Pa... |